The diagnosis and treatment of diseases of the stomach and intestines / by William Fitch Cheney.

  • Cheney, William Fitch, 1866-1941.
Date:
[1936], ©1936
Catalogue details

Licence: Public Domain Mark

Credit: The diagnosis and treatment of diseases of the stomach and intestines / by William Fitch Cheney. Source: Wellcome Collection.

    80/400 (page 64)
    monohydrochloride, which has been extensively advertised to the medical profession under the trade name larostidin. This remedy is to be given by parenteral injection, daily or every other day, until twenty-four ampoules of 5 c.c. each are admin¬ istered. Reports on the use of this remedy have not been altogether satisfactory. Among the most recent is that by Sand- weiss of Detroit (Jour. A. M. A., April 25, 1936, p. 1452), who treated 40 patients by this method. The objections he finds to it are its cost, the fact that twenty-four visits by the patient to the office or clinic are required, that in an appreciable number of cases mild reactions are produced, such as weakness, weari¬ ness and various aches and pains, that there is a high percentage of recurrence of symptoms within six months after treatment, and that approximately the same percentage of patients respond favorably to the diet-alkali regime without histidine. It pro¬ duced remission of symptoms in 55 per cent, of the group treated by Sandweiss, but did not prolong the symptom-free interval nor prevent recurrence, and 85 per cent, of patients, who de¬ veloped remissions, returned with ulcer symptoms within six months after treatment. The remedy may be used in cases not responding to the dietetic, alkali, anti-spasmodic routine com¬ monly employed, but only for temporary relief, not for cure, because in 24 patients checked by x-ray or by operation after finishing the course of histidine, Sandweiss found that not one showed disappearance of the ulcer deformity. Almost identical conclusions are reached by Martin of New York (Jour. A. M. A. April 25, 1936, p. 1468). Of 41 cases treated by histidine 30 were symptom free at the end of four weeks, but 24 of these 30 had one or more relapses within ten months. It is significant that the Council on Pharmacy and Chemistry of the American Medical Association has found larostidin not acceptable for in-